Flovent

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flovent

The medicine known commercially as Flovent, which contains the active ingredient Fluticasone Propionate, is an essential Inhaled Corticosteroid (ICS) preparation used for the long-term control and prophylaxis of chronic airway conditions.


Quick Facts

Property Description
Active Ingredient Fluticasone Propionate
Form Pressurized Inhalation Aerosol or Inhalation Powder
Pharmacological Class Glucocorticoid, Anti-inflammatory agent
Common Use Long-term maintenance of airway function
Origin Synthetic fluorinated steroid derivative

What Type of Medicine is Fluticasone Propionate?

Fluticasone Propionate is a synthetic glucocorticoid that functions as an anti-inflammatory agent specifically targeting the respiratory tract when delivered via inhalation. This compound is chemically classified as a potent corticosteroid and is a single-ingredient product in this formulation. Its design as a locally active ICS distinguishes its physiological action from systemically absorbed oral or injected steroids. As a foundational tool for managing chronic respiratory disease, this medication is clinically recognized for its role in long-term respiratory care.

Active Ingredient and Inhalation Formulations

The active ingredient, micronized Fluticasone Propionate, is prepared for delivery via specialized inhalation devices designed for the oral inhalation route. Flovent formulations, such as Flovent HFA and Flovent Diskus, represent two primary dosage forms: the Pressurized Inhalation Aerosol and the Inhalation Powder. These sophisticated delivery systems ensure the Fluticasone Propionate is precisely deposited into the bronchial tissues. The drug’s anti-inflammatory mechanism works by regulating inflammation within the lungs.

General Purpose: Long-Term Airway Control

The primary purpose of this medicine is the continuous maintenance and prophylaxis of chronic respiratory symptoms by consistently reducing inflammation. Fluticasone Propionate is a non-rescue medication, meaning it cannot treat an acute breathing emergency. Its sustained anti-inflammatory effect works over time to reduce bronchial hyper-responsiveness, which helps maintain the sustained function of the airways for both adult patients and pediatric patients requiring long-term management.

Regulatory References

  1. WHO Model List

What side effects are possible with Flovent?

Possible Side Effects and Safety Information

The safety profile of Flovent (fluticasone propionate) Inhalation is defined by officially documented adverse reactions, categorized by frequency and the body system affected, strictly based on regulatory data.


Common and Expected Adverse Reactions

The most frequent side effects, documented as Very Common or Common in clinical data, are primarily related to local use. These include headache, oral and pharyngeal candidiasis (thrush), and hoarseness (dysphonia).

Systemic and Serious Adverse Reactions

While uncommon, the medicine can be absorbed into the body, leading to potential systemic corticosteroid effects. Serious adverse reactions listed in regulatory documents include:

  • Adrenal Suppression: A risk of clinically significant suppression of the hypothalamic-pituitary-adrenal (HPA) axis, particularly with high doses or during transfer from systemic steroids.
  • Immediate Hypersensitivity Reactions: Rare, severe reactions such as anaphylaxis, angioedema, and paradoxical bronchospasm (acute airway narrowing).
  • Other Systemic Effects: Potential for cataracts, glaucoma, and a reduction in bone mineral density with chronic, long-term use.

Safety Constraints and Special Populations

Regulatory labeling establishes specific safety constraints:

Population/Situation Safety Constraint
Pediatrics Requires monitoring of growth velocity due to the potential for growth reduction.
Hepatic Impairment Clearance may be impaired in patients with severe hepatic impairment, increasing the risk of systemic effects.
Acute Episodes Contraindicated for the primary treatment of status asthmaticus or other acute asthma episodes requiring intensive measures.

Patients being transferred from systemic corticosteroids require careful monitoring for signs of adrenal insufficiency.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation on Fluticasone Propionate overdose distinguishes between acute and chronic exposure patterns. Acute overdose, resulting from excessively high doses over a short period, may lead to a transient increase in systemic corticosteroid effects, a condition generally requiring observation only.

Overdose Scenario Documented Outcome/Manifestation
Acute Overdose Transient increase in systemic corticosteroid effects
Chronic Overdose Suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis, Cushingoid features

Chronic overdose, which occurs after prolonged exposure to higher-than-prescribed doses, is a more serious concern, leading to the suppression of the HPA axis. This physiological state carries the risk of adrenal insufficiency and a severe, potentially life-threatening complication known as an adrenal crisis, particularly when the patient experiences stress.

When to Seek Immediate Medical Attention

Immediate medical attention must be sought for any suspected or confirmed signs of HPA axis suppression or an impending adrenal crisis, as stated in regulatory guidance. Specialized monitoring, such as of adrenal reserve, may be required in cases of chronic overdose. Management is officially described as symptomatic and supportive treatment, often involving the gradual reduction of the medication to allow for the recovery of HPA axis function. Regulatory labels note that no specific antidote is known for this overdose. Pediatric patients are officially recognized as being potentially more susceptible to HPA axis suppression.

Therapeutic Uses of Flovent

What Flovent Treats: Main Uses and Benefits

Flovent is commonly used for the long-term management of asthma, which is a condition characterized by periods of heightened symptoms and involves inflammatory or irritative processes. The medication is used to provide long-term support for asthma in patients aged 4 years and older. It is relevant for easing symptoms related to heightened physiological activity, such as wheezing, shortness of breath, and coughing.


Supportive Symptom Management

Flovent is applied across therapeutic domains where additional symptomatic support is needed. It helps address symptom clusters that may become intense or disruptive, which is relevant for managing conditions involving episodic or fluctuating manifestations. This use is often during phases when symptoms become more noticeable, providing consistent, long-term support that assists with maintaining functional stability and supports general well-being during symptomatic phases. It helps patients cope more steadily with symptom fluctuations, contributing to improved day-to-day comfort during periods of heightened symptoms.

Symptom Focus: Managing Airway Discomfort

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Flovent?

The population eligibility for Flovent (fluticasone propionate inhalation) is defined strictly by regulatory labeling, focusing on age, acute disease status, and specific comorbidities. The medicine is primarily approved for long-term maintenance treatment of asthma.

Contraindications and Non-Eligibility

Flovent is contraindicated for the primary treatment of status asthmaticus or any other acute episodes of asthma that require intensive rescue measures. It must not be used by patients with a known hypersensitivity to fluticasone propionate or any component of the formulation.


Age and Organ Function Rules

Population Group Regulatory Status
Pediatric Patients (<4 years) Safety and efficacy not established for maintenance treatment.
Approved Age Group Patients 4 years of age and older.
Hepatic Impairment Conditional use; close monitoring required due to hepatic metabolism.

Special Populations and Restrictions

Use requires caution in patients with concurrent, untreated systemic infections, including active or quiescent tuberculosis, fungal, bacterial, or viral infections. During pregnancy and lactation, use is permitted only when a healthcare professional determines that the potential benefit justifies the potential risk, as data are generally inadequate.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Flovent's active ingredient is metabolized through the Cytochrome P450 3A4 (CYP3A4) enzyme system in the liver. Official regulatory documents indicate that co-administration with strong inhibitors of this enzyme can significantly increase the systemic exposure to the medicine, which may lead to systemic corticosteroid effects.

Category
Strong CYP3A4 Inhibitors

Co-administration with potent CYP3A4 inhibitors, such as ritonavir, is specifically documented to increase plasma concentrations of Flovent by several hundredfold, resulting in notably reduced serum cortisol levels. Due to the high risk of systemic corticosteroid adverse effects, including Cushing's syndrome and adrenal suppression, the use of Flovent with strong CYP3A4 inhibitors is generally not recommended or should be avoided unless the potential benefit is determined to outweigh the risk.

Other listed examples of strong CYP3A4 inhibitors include atazanavir, clarithromycin, indinavir, itraconazole, nelfinavir, saquinavir, ketoconazole, and voriconazole. When co-administration is considered necessary, patients are advised to be closely monitored for signs of systemic corticosteroid effects. This constraint establishes the clinically significant nature of the interaction within the official drug interaction profile.

Mechanism of Action

Mechanistic Action: Glucocorticoid Receptor Agonism

The drug fluticasone propionate functions as an agonist that binds to intracellular glucocorticoid receptors within the cells of the airways. This interaction initiates a molecular cascade where the drug-receptor complex enters the nucleus and directly modulates gene transcription. This process results in the upregulation of genes encoding anti-inflammatory proteins and the simultaneous downregulation of genes encoding inflammatory mediators such as cytokines and chemokines.

This genomic effect results in the suppression of inflammatory signaling by inhibiting the activity and migration of immune cells, including eosinophils and T-lymphocytes, and blocking the secretion of their chemical components. The resulting system-level physiological consequence is the lessened tissue fluid accumulation (edema) and diminished mucus gland secretion in the airway lining, which leads to an adjustment of the structural caliber and tissue reactivity of the air passages.

Dosage and Administration Information

How Flovent is Used: General Administration Guidelines

Fluticasone Propionate (Flovent) is exclusively administered via the oral inhalation route and is intended solely for long-term maintenance treatment, not for addressing acute respiratory distress. The standard protocol requires dosing twice daily (BID), typically separated by approximately 12 hours. Dosage is initiated based on prior therapy and must be titrated to the lowest effective dosage to sustain control once stability is achieved, a core principle of usage defined in the prescribing information.


Standard Usage Procedures

Feature Standard Procedure Summary
Dosing Frequency Twice daily administration (BID).
Post-Inhalation Step Patients must rinse their mouth with water without swallowing immediately after each dose.
HFA Preparation The Flovent HFA inhaler must be primed with four test sprays before its first use; it must be reprimed with one spray if unused for more than 7 days.
Missed Dose Rule If a dose is missed, it should be skipped, and the patient should resume the regular schedule. The dose must not be doubled.

Population and Transition Rules

Flovent is not for use in children under 4 years of age. For young patients receiving the HFA formulation, a valved holding chamber and mask may be used to assist administration. Patients transferring from chronic oral corticosteroid therapy must undergo a slow, gradual reduction of the systemic steroid dose while monitoring is performed. Full beneficial effects may require 1 to 2 weeks or longer of continuous usage.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flovent (Fluticasone Propionate)

The clinical evaluation of Fluticasone Propionate (Flovent) is based on extensive research, primarily focusing on its study as a therapy for long-term management of chronic asthma. This body of research includes numerous high-quality Randomized Controlled Trials (RCTs) and scientific systematic reviews and meta-analyses that consolidate findings across many studies.


Evidence for Long-term Asthma Maintenance and Control

Research exploring how symptoms change over time has primarily involved trials comparing Fluticasone Propionate against a placebo or against other active inhaled steroids. Studies were conducted during periods of increased symptom activity and throughout maintenance phases, monitoring measured changes in the observed populations. Researchers examined outcomes related to physiological strain and functional imbalance, specifically focusing on measures of lung function like FEV1 (Forced Expiratory Volume in 1 second) and PEF (Peak Expiratory Flow).

In these studies, findings describe patterns observed in the participants' lung function and patient-reported outcomes describing perceived discomfort. Research highlights measurements during the study period, including the documented frequency of severe asthma attacks (exacerbations) and the reported use of short-acting rescue inhalers. Research also describes patterns related to symptom intensity or variability, often indicating that the largest differences in measured outcomes were documented at low to intermediate doses.

What remains uncertain is the full characterization of the dose-response relationship across all individuals, especially at the high-dose end. Long-term data from highly controlled Randomized Controlled Trials remains limited, meaning the long-term effects are not fully established and require continued observation.


Evidence for Oral Corticosteroid (OCS) Reduction

Specific research was evaluated in patients with severe, chronic asthma who were dependent on regular systemic Oral Corticosteroids (OCS). The studies explored the ability to adjust or lower the required amount of these systemic medications. The primary outcome monitored in this research was the potential for OCS dose change—the measured amount by which the maintenance OCS dose was evaluated for adjustment.

Findings describe patterns where the use of high-dose inhaled therapy coincided with changes in the required daily OCS dose in some cases. Because the population studied is small and complex, the sample sizes were modest, and the evidence for this specific scenario is considered to have a moderate certainty.

Key Studies & References Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations (Systematic Review/NMA)

Frequently Asked Questions (FAQ)

Common questions about Flovent (FAQ)


Q: What are common side effects people notice when first starting Flovent?

Official product information lists common side effects observed in clinical studies, which include headache, oral candidiasis (thrush), and hoarseness. These side effects are generally reported, but official documents do not specify whether these effects occur only upon initiation of therapy. Regulatory documents provide a full safety profile describing the frequency of all reported reactions.


Q: Can Flovent cause changes in mood or sleep?

Official regulatory documents indicate that psychiatric effects have been reported rarely with fluticasone use. These rare effects include reports of depression, anxiety, and sleep disorders. Behavioral changes, such as hyperactivity or irritability, are also described in official product information.


Q: Is it common to see weight gain related to Flovent use?

Regulatory data indicates that weight gain has been reported as a rare side effect of the medicine. The effect is generally considered to be related to systemic absorption, which is limited with inhaled corticosteroids. It is not listed among the very common side effects found in clinical studies.


Q: Is there any information about Flovent interacting with grapefruit products?

Official regulatory documents note that grapefruit juice is a strong inhibitor of the enzyme that metabolizes the active ingredient in Flovent. Co-administration may result in increased systemic exposure to the active ingredient. This increased exposure raises the potential for systemic corticosteroid side effects.


Q: Is there a maximum age limit for using Flovent?

The medicine is approved for the long-term maintenance treatment of asthma in patients who are 4 years of age and older. Regulatory documents define the minimum age for use but do not specify a maximum age or cutoff point for the continued use of Flovent.


Q: Is Flovent used only for asthma, or does it have other common uses?

According to the official labeling, Flovent is indicated solely for the continuous, long-term maintenance treatment of asthma. The official product labeling does not describe the use of the medicine for any other condition.


Q: Is there a generic version of Flovent available?

Official regulatory sources confirm that authorized generic versions of the active ingredient, fluticasone propionate, have been made available by the manufacturer. These authorized generic options, for both HFA and Diskus formulations, are listed in regulatory sources such as DailyMed.


Q: Is it possible to become dependent on Flovent?

Regulatory documents describe a risk of adrenal suppression, a condition where the body’s natural steroid production is reduced, particularly when high doses are used. This risk is why regulatory guidance emphasizes close monitoring and gradual adjustment when transferring patients from systemic steroids.


Q: Can Flovent be used for exercise-induced breathing issues?

Official labeling states that Flovent is indicated exclusively for the maintenance treatment of asthma. It is specifically noted that the medicine is not intended for the relief of acute breathing problems, including exercise-induced bronchospasm.


Q: Is it necessary to shake the inhaler before using Flovent?

Official patient instructions indicate that the Flovent HFA inhaler must be shaken well for 5 seconds before each spray during the priming or repriming process. This step is necessary for the aerosol device. The Flovent Diskus device, which is a dry powder inhaler, does not require shaking.


Q: Does using Flovent affect the immune system generally?

Regulatory warnings state that fluticasone propionate can cause immunosuppression when absorbed into the body. Official documents note that this systemic effect may potentially worsen certain existing conditions, such as tuberculosis and other fungal, bacterial, viral, or parasitic infections.


Q: Are there any specific concerns about using Flovent in teenagers?

The regulatory labeling does not have a separate section focused specifically on teenagers as a distinct group. However, some behavioral changes like irritability and hyperactivity, which are listed as rare adverse effects, are noted to be predominantly reported in the pediatric population.


Q: Does Flovent contain lactose or other common allergens?

The official product information confirms that the Flovent Diskus (inhalation powder) formulation contains lactose. Use of this product is restricted for patients with a known severe hypersensitivity to milk proteins. The Flovent HFA (aerosol) formulation does not contain lactose.

How should Flovent be stored and disposed of?

How to Store and Dispose of Flovent?

The storage and disposal instructions for Flovent are defined by regulatory labeling to ensure product stability and safety. Both Flovent HFA and Flovent Diskus must be stored out of the reach of children.

Flovent HFA (Aerosol)

Store the pressurized canister at controlled room temperature (59 F to 86 F). The canister must be protected from excessive heat and must not be frozen. It must never be punctured, incinerated, or thrown into a fire; disposal must follow local regulations.

Flovent Diskus (Powder)

Store the device inside the original, unopened moisture-protective foil pouch. After opening, discard the device after all doses are used or within a specific time period (e.g., 2 months for 100/250 mcg strengths), whichever comes first. Do not store the device in moist areas.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flovent found in:

A-Z Index: